ASCO 2024 - Warner Biddle and Ibrahim Elhoussieny

ASCO is always an interesting show for KITE Therapeutics, the Gilead Sciences subsidiary focused on cell therapy. At ASCO23 we caught up with KITE’s head of commercial affairs, Warner Biddle, and this year Editor in Chief Jonah Comstock was able to speak to Head of Medical Affairs Dr Ibrahim Elhoussieny as well.
In the video interview below, recorded live at ASCO 2024 in Chicago, Illinois, the two of them discuss new data from the longterm follow-up of the ZUMA-3 trial for Tecartus (brexucabtagene autoleucel), which showed 40% survival at the 4-year mark. They also talk about new foundational data looking at Yescarta (axticabtagene ciloleucel) in CND lymphoma. And we get a taste of what’s to come as KITE thinks about the next generation of CAR-Ts, exploring advances in dual targeting and faster manufacturing.
As well as the news, Biddle, Elhoussieny, and Comstock talk trends, from cell therapy infrastructure and authorised treatment centres to research trends at the conference. There’s lots to cover in this energetic on-site sit-down from ASCO, so take a look below.
Subscribe to the pharmaphorum CZcams channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/